{
    "2019-08-30": [
        [
            {
                "time": "2018-09-04",
                "original_text": "It’s Time to Short Johnson & Johnson Stock",
                "features": {
                    "keywords": [
                        "short",
                        "Johnson & Johnson",
                        "stock"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-09-05",
                "original_text": "Dow Jones Rallies On China Trade Hopes; J&J Opioid Ruling, Best Buy, Burlington Stores, Ulta Beauty Earnings: Weekly Review",
                "features": {
                    "keywords": [
                        "Dow Jones",
                        "rallies",
                        "China trade",
                        "J&J",
                        "opioid",
                        "earnings"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance",
                        "retail",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-06",
                "original_text": "How the Johnson & Johnson Ruling Could Affect the Opioid Cases",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "ruling",
                        "opioid cases"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "legal"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-07",
                "original_text": "Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs",
                "features": {
                    "keywords": [
                        "pharma stock",
                        "JNJ",
                        "opioid lawsuit",
                        "regulatory nod"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-08",
                "original_text": "AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Rova-T",
                        "lung cancer",
                        "study fails"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-09",
                "original_text": "3 Large-Cap Stocks to Sell in September",
                "features": {
                    "keywords": [
                        "large-cap stocks",
                        "sell",
                        "September"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-09-10",
                "original_text": "Purdue eyeing $12 billion settlement for 2,000 lawsuits",
                "features": {
                    "keywords": [
                        "Purdue",
                        "settlement",
                        "lawsuits"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "legal"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-11",
                "original_text": "Will Opioid Litigation Take its Toll on Pharma Companies?",
                "features": {
                    "keywords": [
                        "opioid litigation",
                        "pharma companies"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "legal"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-12",
                "original_text": "Phibro Animal Health Corporation (PAHC) Ex-Dividend Date Scheduled for September 03, 2019",
                "features": {
                    "keywords": [
                        "Phibro Animal Health",
                        "ex-dividend date"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "agriculture",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-13",
                "original_text": "Litigation alone cannot heal the opioid epidemic",
                "features": {
                    "keywords": [
                        "litigation",
                        "opioid epidemic"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "social issues"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "A selection of the FT’s biggest stories and best reads every Friday",
                "features": {
                    "keywords": [
                        "FT",
                        "stories",
                        "reads"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "general news"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-09-15",
                "original_text": "Papa John's Is Ready for Its Turnaround",
                "features": {
                    "keywords": [
                        "Papa John's",
                        "turnaround"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "food service",
                        "retail"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}